Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The Migraine management in Poland Jacek Rozniecki Dept. of Neurology Medical University in Lodz Country description • • Demography – 38 mln Economy – GDP (Gross Domestic Product) – 1047 mld (bln) PLN = $385 mld (bln) – GDP/capita = $10 200 – HC expenditure – 7% GDP/capita = $744 % of population in „new” EC countries Health care system • Description of key Regulatory/Reimbursement assumptions – – – – – Free of charge (epilepsy*, PD, MG) Lump (epilepsy**) (~$1) 30% reimbursement 50% reimbursement Full charge • Reimbursement/ triptans – Full charge, no reimbursement The role of Headache Society, Centers and Specialists in migraine management • Migraine Investigation Section of the Polish Neurological Society • Polish Headache Society (in the structure of IHF) – National congresses of PHS – International conferences of PHS – Pharmaco-meetings • Treatment – „old guidlines“, „new guidlines“ - in progress • Education – – – – – Headache Academy (for neurologists) School of Headache (for GPs) Headache courses for neurological specialty Booklets for headache patients Polish Headache Association • Headache centers – Lodz, Warsaw (3), Lublin, Poznan, Gdansk The role of GPs in migraine management (supposed to be) • Part in migraine treatment – – – – – First-line physician Direct and fast contact No need for diagnostics No need for special conditions for routine patients care No restrictions in terms of pharmaceuticals prescrptions • Education – Courses, and cooperation with a neurologist • Guidelines – The same as for neurologists Headache care system - view of GP (The questionnaire prepared by Goril Bruvik Gravdahi from Norvegian National Headache Centre Department of Neurology and Clinical Neurophysiology Trondheim, Norway) Headache care system - view of GP Headache care system - view of GP Headache care system - view of GP „Current“ situation in migraine therapy Yearly worldwide units (millions) Ergotamine-based compounds NSAIDs, aspirin and others Narcotic-based compounds Triptans 1 800 1 600 1 400 1 200 1 000 800 600 400 200 0 1995 1996 1997 1998 1999 Guidetti V., MSD Symposium, Barcelona 2001 The migraine awareness among population • Specialist – Continuous education – Easy access to up to date clinical research data, publications, EBM guidlines – Participation in clinical and scientific meetings • GPs – Continuous education – Possibility of quick consultation with a neurologist and/or headache specialist – Motivation of not sending a patient to a specialist • Patients – – – – – – Easy access to popular medical publications about common primary headaches Access to simple self-evaluation/self-diagnostic tools Patients‘ associations Easy access to patients‘ internet forum Enough of doctor‘s time for a patient Patients‘ trust in their GP The POSSIBILITIES how to IMPROVE it! • Key activities: – Education, awareness and info for – Neurologists – GPs – Patients – Guidelines, EBM – Referal system for consultations with neurologists and headache specialists – Internet forum and consultations – National headache journal widely open for neurologists as well GPs • International cooperation – Guidelines – Meetings – International headache journals subscrptions • Free market mechanisms for triptans The POSSIBILITIES how to IMPROVE it! • Maxalt (rizatriptan) - $ 13/ tab = Euro 9/ tab • Zomig (zolmitriptan) - $ 12/ tab = Euro 8,7/ tab • Relpax (eletriptan) - $ 7,5/ tab = Euro 5,2/ tab • • • • • Imigran (sumatriptan) – $ 6,5/ tab = Euro 4,7/ tab Sumamigren (sumatriptan) - $ 5,9/ tab = Euro 4,2/ tab Sumigra (sumatriptan) – $ 5,2/ tab = Euro 3,9/ tab Cinie (sumatriptan) - $ 3,3/ tab = Euro 2,4/ tab ............................... - $ 1,4/ tab = Euro 1/ tab or reimbursements (realistically – no chance!)